Search

Your search keyword '"Zinman, Bernard"' showing total 768 results
Start Over Author "Zinman, Bernard" Publisher american diabetes association
768 results on '"Zinman, Bernard"'

8. 249-OR: Growth Trajectories of MiTy Kids' Offspring According to Intrauterine Growth Status

Author

SANCHEZ, J. JOHANNA, primary, HAMILTON, JILL, additional, TOMLINSON, GEORGE, additional, ASZTALOS, ELIZABETH, additional, MURPHY, KELLIE, additional, ZINMAN, BERNARD, additional, SIMMONS, DAVID, additional, HAQQ, ANDREA, additional, FANTUS, IVAN G., additional, LIPSCOMBE, LORRAINE, additional, ARMSON, ANTHONY, additional, BARRETT, JON F.R., additional, DONOVAN, LOIS E., additional, KARANICOLAS, PAUL, additional, JIANG, YIDI, additional, TOBIN, SIOBHAN, additional, MANGOFF, KATHRYN, additional, KLEIN, GAIL, additional, and FEIG, DENICE, additional

Published
2022
Full Text
View/download PDF

9. 248-OR: MiTy Kids: Follow-Up of Offspring Exposed to Metformin In-Utero in Mothers with Type 2 Diabetes in the MiTy Trial

Author

FEIG, DENICE, primary, SANCHEZ, J. JOHANNA, additional, MURPHY, KELLIE, additional, ASZTALOS, ELIZABETH, additional, ZINMAN, BERNARD, additional, SIMMONS, DAVID, additional, HAQQ, ANDREA, additional, FANTUS, IVAN G., additional, LIPSCOMBE, LORRAINE, additional, ARMSON, ANTHONY, additional, BARRETT, JON F.R., additional, DONOVAN, LOIS E., additional, KARANICOLAS, PAUL, additional, KLEIN, GAIL, additional, TOBIN, SIOBHAN, additional, MANGOFF, KATHRYN, additional, TOMLINSON, GEORGE, additional, and HAMILTON, JILL, additional

Published
2022
Full Text
View/download PDF

13. Risk of Foot Ulcer and Lower-Extremity Amputation Among Participants in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study

Author

Boyko, Edward J., primary, Zelnick, Leila R., additional, Braffett, Barbara H., additional, Pop-Busui, Rodica, additional, Cowie, Catherine C., additional, Lorenzi, Gayle M., additional, Gubitosi-Klug, Rose, additional, Zinman, Bernard, additional, and de Boer, Ian H., additional

Published
2022
Full Text
View/download PDF

14. Association of Estimated Time-in-Range Capillary Glucose Levels Versus HbA1c With Progression of Microvascular Complications in the Diabetes Control and Complications Trial.

Author

Lachin, John M., Bebu, Ionut, Gao, Xiaoyu, Nathan, David M., Zinman, Bernard, and Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group

Subjects
BLOOD sugar monitoring, TYPE 1 diabetes, BLOOD sugar, RESEARCH funding, DIABETIC retinopathy, DISEASE complications
Abstract

Objective: Estimated time in range (eTIR) obtained from DCCT glucose profiles (pre- and postprandial and bedtime) was recently reported to be associated with microvascular outcomes and was recommended as a clinical trial outcome, but without consideration of HbA1c.Research Design and Methods: The associations of eTIR with diabetic retinopathy and microalbuminuria were assessed without and with adjustment for HbA1c and baseline covariates.Results: Adjusted for HbA1c and covariates, eTIR was marginally significantly associated with retinopathy in the full cohort (hazard ratio [HR] 1.12 per 10% lower eTIR [95% CI 1.0, 1.26], P = 0.042). Conversely, HbA1c was significantly associated with both outcomes (HR ≥1.19 per 0.5% higher HbA1c, P ≤ 0.0002) in five of six adjusted analyses.Conclusions: The association of eTIR with complications is largely explained by its correlation with HbA1c. HbA1c, not eTIR or continuous glucose monitoring TIR, remains the preferred outcome in clinical studies of type 1 diabetes complications. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

16. 133-LB: Canagliflozin Improves Cardiovascular and Renal Outcomes across Broad Geographic Regions: Results from CREDENCE

Author

CARDOZA, KATHRYN, primary, KANG, AMY, additional, SMYTH, BRENDAN, additional, YI, TAE WON, additional, TANNA, GIAN LUCA DI, additional, POLLOCK, CAROL A., additional, DE ZEEUW, DICK, additional, WHEELER, DAVID C., additional, CANNON, CHRISTOPHER P., additional, ZINMAN, BERNARD, additional, JARDINE, MEG J., additional, ARNOTT, CLARE, additional, LEVIN, ADEERA, additional, and MAHAFFEY, KENNETH W., additional

Published
2021
Full Text
View/download PDF

17. 131-LB: The Impact of Canagliflozin on the Risk of Neuropathy Events: Results from the CREDENCE Trial

Author

LIAO, JINLAN, primary, KANG, AMY, additional, XIA, CHAO, additional, ARNOTT, CLARE, additional, TANNA, GIAN LUCA DI, additional, KRISHNAN, ARUN V., additional, POLLOCK, CAROL A., additional, AGARWAL, RAJIV, additional, BAKRIS, GEORGE, additional, HEERSPINK, HIDDO L., additional, LEVIN, ADEERA, additional, DE ZEEUW, DICK, additional, NEAL, BRUCE, additional, ZHANG, HONG, additional, WHEELER, DAVID C., additional, ZINMAN, BERNARD, additional, MAHAFFEY, KENNETH W., additional, PERKOVIC, VLADO, additional, JARDINE, MEG J., additional, and SMYTH, BRENDAN, additional

Published
2021
Full Text
View/download PDF

20. Glycemic variability in patients with early type 2 diabetes: the impact of improvement in β-cell function

Author

Kramer, Caroline K., Choi, Haysook, Zinman, Bernard, and Retnakaran, Ravi

Subjects
Diabetes therapy, Pancreatic beta cells, Type 2 diabetes -- Care and treatment, Health
Abstract

OBJECTIVE Increased glycemic variability has been reported to be associated with the risk of hypoglycemia and possibly diabetes complications and is believed to be due to β-cell dysfunction. However, it [...]

Published
2014
Full Text
View/download PDF

21. Glucagon response to oral glucose challenge in type 1 diabetes: lack of impact of euglycemia

Author

Kramer, Caroline K., Borgono, Carla A., Van Nostrand, Paula, Retnakaran, Ravi, and Zinman, Bernard

Subjects
Type 1 diabetes -- Research, Blood sugar -- Research -- Analysis, Glucagon -- Research -- Analysis, Health
Abstract

OBJECTIVE Previous studies have demonstrated aberrant glucagon physiology in the setting of type 1 diabetes (T1D) but have not addressed the potential impact of ambient glycemia on this glucagon response. [...]

Published
2014
Full Text
View/download PDF

22. Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions

Author

Nathan, David M., Bayless, Margaret, Cleary, Patricia, Genuth, Saul, Gubitosi-Klug, Rose, Lachin, John M., Lorenzi, Gayle, and Zinman, Bernard

Subjects
Diabetes therapy -- Methods -- Forecasts and trends, Diabetes -- Research, Market trend/market analysis, Health
Abstract

The Diabetes Control and Complications Trial (DCCT) (1) and its observational follow-up, the Epidemiology of Diabetes Interventions and Complications (EDIC) Study (2), are celebrating the 30th anniversary since the start [...]

Published
2013
Full Text
View/download PDF

23. Short leg length, a marker of early childhood deprivation, is associated with metabolic disorders underlying type 2 diabetes: the promise cohort study

Author

Johnston, Luke W., Harris, Stewart B., Retnakaran, Ravi, Gerstein, Hertzel C., Zinman, Bernard, Hamilton, Jill, and Hanley, Anthony J.

Subjects
Medical research -- Physiological aspects -- Analysis, Medicine, Experimental -- Physiological aspects -- Analysis, Glucose tolerance tests -- Physiological aspects -- Analysis, Dextrose -- Physiological aspects -- Analysis, Glucose -- Physiological aspects -- Analysis, Glucose metabolism -- Physiological aspects -- Analysis, Type 2 diabetes -- Research -- Physiological aspects -- Analysis, Health, University of Toronto
Abstract

OBJECTIVE--Short leg length, a marker of early childhood deprivation, has been used in studies of the association of early life conditions with adult chronic disease risk. The objective of this [...]

Published
2013
Full Text
View/download PDF

24. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

Author

Nathan, David M., Buse, John B., Davidson, Mayer B., Ferrannini, Ele, Holman, Rury R., Sherwin, Robert, and Zinman, Bernard

Subjects
Merck & Company Inc. -- Management, Pfizer Inc. -- Management, Novartis AG -- Management, Eli Lilly and Co. -- Management, Diabetes therapy, Thiazolidinediones, Type 2 diabetes -- Development and progression -- Care and treatment, Hyperglycemia -- Development and progression -- Care and treatment, Algorithms, Pharmaceutical industry, Company business management, Algorithm, Health, American Diabetes Association -- Management
Abstract

The consensus algorithm for the medical management of type 2 diabetes was published in August 2006 with the expectation that it would be updated, based on the availability of new [...]

Published
2009

25. Treating Gestational Diabetes Reduces Birth Weight but Does Not Affect Infant Adiposity Across the 1st Year of Life.

Author

Retnakaran, Ravi, Ye, Chang, Hanley, Anthony J., Connelly, Philip W., Sermer, Mathew, Zinman, Bernard, and Hamilton, Jill K.

Subjects
FETAL macrosomia, CHILDHOOD obesity, BLOOD sugar, WEIGHT gain, BIRTH weight, RESEARCH funding, GESTATIONAL diabetes, ADIPOSE tissues
Abstract

Objective: The continuum of maternal glycemia in pregnancy shows continuous associations with both 1) neonatal birth weight at delivery and 2) subsequent adiposity later in childhood. While treating gestational diabetes mellitus (GDM) can lower birth weight and thereby disrupt the former association, it is unclear if such treatment reduces childhood adiposity. Thus, we sought to compare anthropometry across the 1st year of life between infants born to women who were treated for GDM and those with lesser degrees of gestational dysglycemia (untreated).Research Design and Methods: Anthropometric measurements were performed at 3 months and 12 months of life in 567 infants born to women comprising the following four gestational glucose tolerance groups: 1) women with normoglycemia on both glucose challenge test (GCT) and oral glucose tolerance test (OGTT) in pregnancy; 2) women with an abnormal GCT but normal OGTT; 3) those with mild gestational impaired glucose tolerance; and 4) women treated for GDM.Results: Birth weight progressively increased across the three untreated groups but was lowest in women treated for GDM (P = 0.0004). Similarly, women treated for GDM had the lowest rate of macrosomia (P = 0.02). Conversely, however, there were no differences among the four groups in weight z score, length z score, weight-for-length z score, or BMI z score at either 3 months or 12 months (all P values = NS). Similarly, there were no differences among the groups in triceps/biceps/subscapular/suprailiac skinfold thickness or sum of skinfolds at either 3 months or 12 months (all P values = NS).Conclusions: Despite reducing birth weight and macrosomia, the treatment of GDM does not have analogous effects on infant adiposity across the 1st year of life. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

26. The Impact of Empagliflozin on Obstructive Sleep Apnea, Cardiovascular, and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial

Author

Neeland, Ian J., primary, Eliasson, Bjorn, primary, Kasai, Takatoshi, primary, Marx, Nikolaus, primary, Zinman, Bernard, primary, Inzucchi, Silvio E., primary, Wanner, Christoph, primary, Zwiener, Isabella, primary, Wojeck, Brian S., primary, Yaggi, Henry K, primary, Johansen, Odd Erik, primary, and investigators, the EMPA-REG OUTCOME®, primary

Published
2020
Full Text
View/download PDF

27. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial

Author

Neeland, Ian J., primary, Eliasson, Bjorn, additional, Kasai, Takatoshi, additional, Marx, Nikolaus, additional, Zinman, Bernard, additional, Inzucchi, Silvio E., additional, Wanner, Christoph, additional, Zwiener, Isabella, additional, Wojeck, Brian S., additional, Yaggi, Henry K., additional, and Johansen, Odd Erik, additional

Published
2020
Full Text
View/download PDF

28. Circulating vitamin D metabolites and subclinical atherosclerosis in type 1 diabetes

Author

Sachs, Michael C., Brunzell, John D., Cleary, Patricia A., Hoofnagle, Andrew N., Lachin, John M., Molitch, Mark E., Steffes, Michael W., Zinman, Bernard, and de Boer, Ian H.

Subjects
Cholesterol, Alfacalcidol, Type 1 diabetes -- Diet therapy, Calcifediol, Vitamin D, Metabolites, Diabetics -- Diet therapy, Atherosclerosis -- Diet therapy, Health
Abstract

OBJECTIVE--People with type 1 diabetes are at high risk of premature atherosclerosis. Existing evidence suggests that impaired vitamin D metabolism may contribute to the development of atherosclerosis. We tested associations [...]

Published
2013
Full Text
View/download PDF

29. Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes.

Author

Perkins, Bruce A., Bebu, Ionut, Gao, Xiaoyu, Karger, Amy B., Hirsch, Irl B., Karanchi, Harsha, Molitch, Mark E., Zinman, Bernard, Lachin, John M., and de Boer, Ian H.

Subjects
TYPE 1 diabetes, GLOMERULAR filtration rate, CARDIOLOGICAL manifestations of general diseases, MAJOR adverse cardiovascular events, INSULIN pumps, KIDNEY transplantation, DIABETES complications, CHRONIC kidney failure complications, CLINICAL trials, KIDNEYS, CARDIOVASCULAR diseases, CARDIOVASCULAR system, ALBUMINURIA, DISEASE complications
Abstract

Objective: Rapid loss of estimated glomerular filtration rate (eGFR) within its normal range has been proposed as a strong predictor of future kidney disease. We investigated this association of eGFR slope early in the course of type 1 diabetes with long-term incidence of kidney and cardiovascular complications.Research Design and Methods: The annual percentage change in eGFR (slope) was calculated during the Diabetes Control and Complications Trial (DCCT) for each of 1,441 participants over a mean of 6.5 years and dichotomized by the presence or absence of early rapid eGFR loss (slope ≤-3% per year) as the exposure of interest. Outcomes were incident reduced eGFR (eGFR <60 mL/min/1.73 m2), composite cardiovascular events, or major adverse cardiovascular events (MACE) during the subsequent 24 years post-DCCT closeout follow-up.Results: At DCCT closeout (the baseline for this analysis), diabetes duration was 12 ± 4.8 years, most participants (85.9%) had normoalbuminuria, mean eGFR was 117.0 ± 13.4 mL/min/1.73 m2, and 149 (10.4%) had experienced early rapid eGFR loss over the preceding trial phase. Over the 24-year subsequent follow-up, there were 187 reduced eGFR (6.3 per 1,000 person-years) and 113 MACE (3.6 per 1,000 person-years) events. Early rapid eGFR loss was associated with risk of reduced eGFR (hazard ratio [HR] 1.81, 95% CI 1.18-2.79, P = 0.0064), but not after adjustment for baseline eGFR level (HR 0.94, 95% CI 0.53-1.66, P = 0.84). There was no association with composite cardiovascular events or MACE.Conclusions: In people with type 1 diabetes primarily with normal eGFR and normoalbuminuria, the preceding slope of eGFR confers no additional association with kidney or cardiovascular outcomes beyond knowledge of an individual's current level. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

30. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long)

Author

Zinman, Bernard, Philis-Tsimikas, Athena, Cariou, Bertrand, Handelsman, Yehuda, Rodbard, Helena W., Johansen, Thue, Endahl, Lars, and Mathieu, Chantal

Subjects
Hypoglycemic agents -- Dosage and administration, Type 2 diabetes -- Drug therapy -- Physiological aspects, Health
Abstract

OBJECTIVE--To compare ultra-long-acting insulin degludec with glargine for efficacy and safety in insulin-naive patients with type 2 diabetes inadequately controlled with oral antidiabetic drugs (OADs). RESEARCH DESIGN AND METHODS--In this [...]

Published
2012
Full Text
View/download PDF

31. Circadian variation in the response to the glucose challenge test in pregnancy implications for screening for gestational diabetes mellitus

Author

Goldberg, Robert J., Ye, Chang, Sermer, Mathew, Connelly, Philip W., Hanley, Anthony J.G., Zinman, Bernard, and Retnakaran, Ravi

Subjects
Glucose tolerance tests -- Health aspects, Diabetes in pregnancy -- Risk factors -- Diagnosis -- Care and treatment, Circadian rhythms -- Health aspects, Pregnant women -- Health aspects, Health
Abstract

OBJECTIVE--A common approach to screening for gestational diabetes mellitus (GDM) is the universal testing of all pregnant women with a l-h, 50-g glucose challenge test (GCT), followed by a diagnostic [...]

Published
2012
Full Text
View/download PDF

33. Effects of linagliptin on cardiovascular and kidney outcomes in people with normal and reduced kidney function: secondary analysis of the CARMELINA randomized trial

Author

Perkovic, Vlado, primary, Toto, Robert, primary, Cooper, Mark E, primary, Mann, Johannes FE, primary, Rosenstock, Julio, primary, McGuire, Darren K, primary, Kahn, Steven E, primary, Marx, Nikolaus, primary, Alexander, John H, primary, Zinman, Bernard, primary, Pfarr, Egon, primary, Schnaidt, Sven, primary, Meinicke, Thomas, primary, Eynatten, Maximillian von, primary, George, Jyothis T, primary, Johansen, Odd Erik, primary, Wanner, Christoph, primary, and investigators, CARMELINA®, primary

Published
2020
Full Text
View/download PDF

34. 27-OR: Effect of Canagliflozin on Total Hospitalization for Heart Failure Events in Patients with Type 2 Diabetes and Chronic Kidney Disease

Author

LI, JINGWEI, primary, JARDINE, MEG J., additional, NEAL, BRUCE, additional, HEERSPINK, HIDDO L., additional, CANNON, CHRISTOPHER, additional, AGARWAL, RAJIV, additional, BAKRIS, GEORGE, additional, CHARYTAN, DAVID M., additional, ZEEUW, DICK DE, additional, EDWARDS, ROBERT, additional, GREENE, TOM, additional, LEVIN, ADEERA, additional, POLLOCK, CAROL A., additional, ROSENTHAL, NORM, additional, WHEELER, DAVID C., additional, ZHANG, HONG, additional, ZINMAN, BERNARD, additional, PERKOVIC, VLADO, additional, MAHAFFEY, KENNETH W., additional, and ARNOTT, CLARE, additional

Published
2020
Full Text
View/download PDF

35. 30-OR: Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME

Author

VADUGANATHAN, MUTHIAH, primary, SATTAR, NAVEED, additional, FITCHETT, DAVID H., additional, OFSTAD, ANNE PERNILLE, additional, BRUECKMANN, MARTINA, additional, GEORGE, JYOTHIS T., additional, VERMA, SUBODH, additional, MATTHEUS, MICHAELA, additional, WANNER, CHRISTOPH, additional, INZUCCHI, SILVIO E., additional, ZINMAN, BERNARD, additional, and BUTLER, JAVED, additional

Published
2020
Full Text
View/download PDF

36. 1144-P: Patient Phenotypes and SGLT2 Inhibition in Type 2 Diabetes Mellitus: Insights from the EMPA-REG OUTCOME Trial

Author

SHARMA, ABHINAV, primary, OFSTAD, ANNE PERNILLE, additional, AHMAD, TARIQ, additional, ZINMAN, BERNARD, additional, ZWIENER, ISABELLA, additional, FITCHETT, DAVID H., additional, WANNER, CHRISTOPH, additional, GEORGE, JYOTHIS T., additional, HANTEL, STEFAN, additional, DESAI, NIHAR, additional, and MENTZ, ROBERT J., additional

Published
2020
Full Text
View/download PDF

40. 1130-P: Mediators of the Effects of Canagliflozin (CANA) on Heart Failure (HF) and CV Death in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD)

Author

LI, JINGWEI, primary, NEAL, BRUCE, additional, HEERSPINK, HIDDO L., additional, ARNOTT, CLARE, additional, CANNON, CHRISTOPHER, additional, AGARWAL, RAJIV, additional, BAKRIS, GEORGE, additional, CHARYTAN, DAVID M., additional, ZEEUW, DICK DE, additional, GREENE, TOM, additional, LEVIN, ADEERA, additional, OH, RICHARD, additional, POLLOCK, CAROL A., additional, WHEELER, DAVID C., additional, YAVIN, YSHAI, additional, ZHANG, HONG, additional, ZINMAN, BERNARD, additional, DI TANNA, GIAN LUCA, additional, PERKOVIC, VLADO, additional, MAHAFFEY, KENNETH W., additional, and JARDINE, MEG, additional

Published
2020
Full Text
View/download PDF

41. 132-LB: Implications of Initial EGFR Response to Empagliflozin Treatment Effects

Author

INZUCCHI, SILVIO E., primary, KRAUS, BETTINA J., additional, WEIR, MATTHEW R., additional, BAKRIS, GEORGE, additional, MATTHEUS, MICHAELA, additional, CHERNEY, DAVID, additional, SATTAR, NAVEED, additional, HEERSPINK, HIDDO L., additional, RITTER, IVANA, additional, EYNATTEN, MAXIMILIAN VON, additional, ZINMAN, BERNARD, additional, WANNER, CHRISTOPH, additional, and KOITKA-WEBER, AUDREY, additional

Published
2020
Full Text
View/download PDF

44. 131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome

Author

INZUCCHI, SILVIO E., primary, ZINMAN, BERNARD, additional, WANNER, CHRISTOPH, additional, FITCHETT, DAVID H., additional, ANKER, STEFAN, additional, POCOCK, STUART, additional, KASPERS, STEFAN, additional, GEORGE, JYOTHIS T., additional, JOHANSEN, ODD ERIK, additional, JAMAL, WAHEED, additional, HANTEL, STEFAN, additional, and LUND, SØREN S., additional

Published
2020
Full Text
View/download PDF

45. 26-OR: Acute Declines in EGFR during Treatment with Canagliflozin and Its Implications for Clinical Practice: Insights from CREDENCE

Author

OSHIMA, MEGUMI, primary, JARDINE, MEG J., additional, AGARWAL, RAJIV, additional, BAKRIS, GEORGE, additional, CANNON, CHRISTOPHER, additional, CHARYTAN, DAVID M., additional, ZEEUW, DICK DE, additional, EDWARDS, ROBERT, additional, GREENE, TOM, additional, LEVIN, ADEERA, additional, MAHAFFEY, KENNETH W., additional, NEAL, BRUCE, additional, POLLOCK, CAROL A., additional, ROSENTHAL, NORM, additional, WHEELER, DAVID C., additional, ZHANG, HONG, additional, ZINMAN, BERNARD, additional, PERKOVIC, VLADO, additional, and HEERSPINK, HIDDO L., additional

Published
2020
Full Text
View/download PDF

46. 926-P: Cardiovascular (CV) and Hypoglycemia Outcomes across Age Groups in People with Type 2 Diabetes (T2D) in the CAROLINA Trial

Author

ESPELAND, MARK, primary, PRATLEY, RICHARD E., additional, ROSENSTOCK, JULIO, additional, KADOWAKI, TAKASHI, additional, SEINO, YUTAKA, additional, ZINMAN, BERNARD, additional, MARX, NIKOLAUS, additional, MCGUIRE, DARREN K., additional, ANDERSEN, KNUT R., additional, MATTHEUS, MICHAELA, additional, KELLER, ANNETT, additional, and JOHANSEN, ODD ERIK, additional

Published
2020
Full Text
View/download PDF

47. 952-P: Incident and Recurrent Hypoglycemia with Linagliptin and Glimepiride in the CAROLINA Trial

Author

ZINMAN, BERNARD, primary, ROSENSTOCK, JULIO, additional, JOHANSEN, ODD ERIK, additional, HOEIBERG, MIKKEL, additional, PFARR, EGON, additional, MATTHEUS, MICHAELA, additional, MEINICKE, THOMAS, additional, GEORGE, JYOTHIS T., additional, ESPELAND, MARK, additional, MCGUIRE, DARREN K., additional, MARX, NIKOLAUS, additional, and KAHN, STEVEN E., additional

Published
2020
Full Text
View/download PDF

48. Cardiovascular risk reduction with liraglutide: an exploratory mediation analysis of the LEADER trial

Author

Buse, John B, primary, Bain, Stephen C, primary, Mann, Johannes FE, primary, Nauck, Michael A, primary, Nissen, Steven E, primary, Pocock, Stuart, primary, Poulter, Neil R, primary, Pratley, Richard E, primary, Linder, Martin, primary, Fries, Tea Monk, primary, Ørsted, David D, primary, Zinman, Bernard, primary, and Investigators, LEADER Trial, primary

Published
2020
Full Text
View/download PDF

49. Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial

Author

Buse, John B., primary, Bain, Stephen C., additional, Mann, Johannes F.E., additional, Nauck, Michael A., additional, Nissen, Steven E., additional, Pocock, Stuart, additional, Poulter, Neil R., additional, Pratley, Richard E., additional, Linder, Martin, additional, Monk Fries, Tea, additional, Ørsted, David D., additional, and Zinman, Bernard, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results